- Report
- April 2023
- 75 Pages
South Korea
From €4241EUR$4,750USD£3,710GBP
- Report
- July 2024
- 100 Pages
Global
From €3348EUR$3,750USD£2,929GBP
- Report
- July 2024
- 100 Pages
Global
From €3348EUR$3,750USD£2,929GBP
- Report
- July 2024
- 100 Pages
Global
From €3348EUR$3,750USD£2,929GBP
- Report
- July 2024
- 150 Pages
Global
From €3348EUR$3,750USD£2,929GBP
- Report
- July 2024
- 150 Pages
Global
From €3348EUR$3,750USD£2,929GBP
- Report
- June 2024
- 200 Pages
Global
From €7097EUR$7,950USD£6,209GBP
- Report
- June 2024
- 200 Pages
Global
From €7097EUR$7,950USD£6,209GBP
- Report
- June 2024
- 200 Pages
Global
From €7097EUR$7,950USD£6,209GBP
- Report
- February 2024
- 244 Pages
Global
From €7097EUR$7,950USD£6,209GBP
- Report
- February 2024
- 119 Pages
Global
From €7097EUR$7,950USD£6,209GBP
- Report
- June 2022
- 320 Pages
Global
From €12409EUR$13,900USD£10,857GBP
- Report
- February 2024
- 131 Pages
Global
From €4241EUR$4,750USD£3,710GBP
- Report
- October 2022
- 110 Pages
Global
From €4241EUR$4,750USD£3,710GBP
- Report
- August 2022
- 117 Pages
Global
From €4241EUR$4,750USD£3,710GBP
- Report
- February 2024
- 120 Pages
Global
From €4241EUR$4,750USD£3,710GBP
- Report
- February 2024
- 110 Pages
Global
From €4241EUR$4,750USD£3,710GBP
- Report
- February 2024
- 71 Pages
Europe
From €4241EUR$4,750USD£3,710GBP
- Report
- February 2024
- 120 Pages
Global
From €4241EUR$4,750USD£3,710GBP
- Report
- April 2023
- 85 Pages
United States
From €4241EUR$4,750USD£3,710GBP

Macular Degeneration is a condition that affects the central part of the retina, known as the macula, which is responsible for sharp, central vision. It is the leading cause of vision loss in people over the age of 50. Optical treatments for Macular Degeneration include laser photocoagulation, photodynamic therapy, and anti-VEGF injections. Laser photocoagulation is used to reduce the risk of further vision loss by sealing off leaking blood vessels in the macula. Photodynamic therapy is used to reduce the growth of abnormal blood vessels in the macula. Anti-VEGF injections are used to reduce the growth of abnormal blood vessels and improve vision.
Companies in the Macular Degeneration market include Novartis, Regeneron, Allergan, Genentech, and Roche. Show Less Read more